Is Mirum Pharmaceuticals, Inc. (MIRM) a Buy, Sell, or Hold?
NASDAQ : MIRM
Mirum Pharmaceuticals, Inc.
$113.03 USD
-$1.33 (-1.16%)
- Volume
- 516.94K
- Average Volume
- 981.64K
- Market Capitalization
- $6.89B
- P/E Ratio
- -8.30
- Dividend Yield
- 0.00%
- Price Target
- $145.50
- Year High
- $130.00
- Year Low
- $50.25
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.09
Company Overview
NASDAQ
Christopher Peetz
Biotechnology
Healthcare
MIRM
418
US
USD
Liquidity Metrics
1.34
2.09
1.99
1.19
0.00
Sales & Valuation
$521.31M
12.10
27.43
-39.95
-2.93
Profitability
-$0.47
-$23.36M
-140.24%
-140.00%
-289.33%
-89.67%
P/E Metrics
-8.30
0.00
0.00
Analyst Price Target & Rating
$145.50
$185.00
$118.00
1/5
18 Analysts
-22.32%
Financial Health Scores
1.09
3/9
$296.61M
$890.92M
$648.42M
-$786.3M
Key Metrics (TTM)
$6.89B
12.10
-9.05
2.09
-289.33%
-11.30%
-12.01%
-2.50%
-31 days
Company Executives
| Name | Title |
|---|---|
| Andrew McKibben | Senior Vice President, Strategic Finance & Investor Relations |
| Jean-Luc Girardet | Chief Technical Officer |
| Lara Longpre | Chief Development Officer |
| Joanne J. Quan | Chief Medical Officer |
| Eric H. Bjerkholt | Chief Financial Officer |
| Peter Radovich | Chief Operating Officer & President |
| Meredith Kiernan | Senior Director of Global Corporate Communications |
| Erin Campany | Chief People Officer |
| Christopher Peetz | Chief Executive Officer & Director |
| Douglas T. Sheehy | Chief Legal Officer & Secretary |
Poll Results
No votes yet today — be the first to share your view!
About Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California. ...
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-13 16:01:00
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its Portfolio
2026-07-04 03:48:41
Mirum Pharmaceuticals is evolving into a leading liver disease franchise, with robust revenue growth and a diversified pipeline targeting high-value indications. MIRM raised its 2026 global sales guidance to $660–$680 million, supported by strong LIVMARLI performance. Recent acquisitions have delayed cash flow positivity to 2028, but the company's pipeline—Volixibat, MRM-3379, and Brelovitug—offers multiple blockbuster opportunities.
Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?
2026-06-29 11:56:13
Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Biotech ETF Index Surges 10% After Rebalance
2026-06-25 11:31:47
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
2026-06-17 07:51:07
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
2026-06-16 04:56:04
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review
2026-06-15 11:45:34
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
2026-06-14 17:00:00
Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced pivotal Phase 2 results from Cohort 1 of the PROGRESS study evaluating zilur
Frequently Asked Questions
-
What is the current Mirum Pharmaceuticals, Inc. (MIRM) stock price?
-
Mirum Pharmaceuticals, Inc.(NASDAQ:MIRM) stock price is $113.03 in the last trading session. During the trading session, MIRM stock reached the peak price of $130 while $50.25 was the lowest point it dropped to. The percentage change in MIRM stock occurred in the recent session was --1.16% while the dollar amount for the price change in MIRM stock was -$1.33.
-
MIRM's industry and sector of operation?
-
The NASDAQ listed MIRM is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of MIRM?
-
Andrew McKibben | Senior Vice President, Strategic Finance & Investor Relations
Jean-Luc Girardet | Chief Technical Officer
Lara Longpre | Chief Development Officer
Joanne J. Quan | Chief Medical Officer
Eric H. Bjerkholt | Chief Financial Officer -
How many employees does MIRM have?
-
Number of MIRM employees currently stands at 418. MIRM operates from 950 Tower Lane, Foster City, CA 94404, US.
-
Link for MIRM official website?
-
Official Website of MIRM is: https://www.mirumpharma.com
-
How do I contact MIRM?
-
MIRM could be contacted at phone #650 667 4085 and can also be accessed through its website. MIRM operates from 950 Tower Lane, Foster City, CA 94404, US.
-
How many shares of MIRM are traded daily?
-
The average number of MIRM shares traded daily for last 3 months was 981.64K.
-
What is the market cap of MIRM currently?
-
The market value of MIRM currently stands at $6.89B with its latest stock price at $113.03